The phase 2, randomized placebo-controlled trial will evaluate safety and efficacy of autologous stromal and vascular fraction cells that are injected after rotator cuff repair. Fifty-six patients are expected to be enrolled.
The Tissue Genesis Icellator was acquired by Orgenesis in 2020. It’s an investigational device in the U.S. and is a system for recovering autologous stromal and vascular fraction cells from fat tissue.
